3 hours ago
The fire occurred at around 10 pm in the company's penicillin-G manufacturing facility in Kakinada SEZ, Andhra Pradesh. No injuries were reported. Shares of Aurobindo Pharma Ltd ended at ₹1,246.75, up by ₹28.90, or 2.37%, on the BSE.
Drug firm Aurobindo Pharma Limited on Monday (April 28) said it has reported a fire incident on April 27, 2025, at its penicillin-G manufacturing facility in Kakinada SEZ, Andhra Pradesh.
The fire occurred around 10 pm IST in the vicinity of the coal crusher area of the facility. The incident resulted in damage to some ancillary equipment, but the core manufacturing infrastructure remained unaffected, and there were no reported injuries.
"On April 27, 2025, at approximately 10:00 PM (IST), a fire incident occurred in the vicinity of the coal crusher area at our Penicillin-G manufacturing facility located in Kakinada SEZ, Thondangi (M), Kakinada District - 533449, Andhra Pradesh, India," Aurobindo Pharma said in a regulatory filing.
Also Read: Aurobindo Pharma shares gain nearly 3% after getting USFDA nod for leukemia drug
The company clarified that the incident is not expected to have a material impact on its operations or financials. A thorough assessment of the damage is currently underway. As a precautionary measure, operations at the plant will be temporarily paused for an estimated period of 20-25 days to facilitate equipment replacements.
The fire was caused by the self-ignition of coal, and investigations are ongoing to determine the exact reasons behind the incident. Aurobindo Pharma noted that the facility is fully insured, and it remains committed to resuming operations at the earliest while adhering to safety and quality standards.
This facility is part of Aurobindo’s wholly-owned step-down subsidiary, Lyfius Pharma Private Limited.
Shares of Aurobindo Pharma Ltd ended at ₹1,246.75, up by ₹28.90, or 2.37%, on the BSE.
Also Read: Aurobindo Pharma's CuraTeQ Biologics completes Phase 1 study of bone drug
(Edited by : Shoma Bhattacharjee)
